SIRP-gamma targeted agents for use in the treatment of cancer
Provided are methods relating to SIRPgamma as a biomarker for cancer cells, and in particular of cancer stem cells and lung adenocarcinoma. Disclosed are also methods of treatment, which involve administering a SIRPgamma targeted agent to a subject with cancer, alone or with another cancer therapy. Methods for diagnosing cancer, identifying subjects with high SIRPgamma levels for treatment, and monitoring SIRPgamma expressing tumors are also provided.
1 . A method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutically effective amount of a composition comprising a signal-regulatory protein gamma (SIRPgamma) targeted antibody.
2 . The method of claim 1 , wherein the SIRPgamma targeted antibody is a monoclonal antibody.
3 . The method of claim 1 , wherein the SIRPgamma targeted antibody is a humanized antibody.
4 . The method of claim 1 , wherein the SIRPgamma targeted antibody comprises a humanized antibody corresponding to any one of antibody LSB2.20 (RRID: AB_1227766), antibody OX119, antibody AF4486, or antibody PA5-47627.
5 . The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
6 . The method of claim 1 , wherein the cancer comprises at least one of lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, a sarcoma, skin cancer, testicular cancer, renal cancer, brain cancer, or leukemia.
7 . The method of claim 6 , wherein the lung cancer comprises bronchogenic cancer, squamous cell carcinoma, small cell lung cancer, adenocarcinoma, or undifferentiated large cell lung cancer.
8 . The method of claim 1 , wherein the method further comprises administering a second form of cancer therapy to the subject.
9 . The method of claim 8 , wherein the second form of cancer therapy comprises a cytotoxic agent, a chemotherapeutic agent, an immunosuppressive agent, or radiation therapy.
10 . The method of claim 8 , wherein the second form of cancer therapy comprises a PDL-1 inhibitor, a PD-1 inhibitor, or a CTLA4 inhibitor.
11 . The method of claim 10 , wherein the PDL-1 inhibitor, the PD-1 inhibitor, or the CTLA4 inhibitor is an inhibitory antibody.
12 . The method of claim 8 , wherein the second form of cancer therapy comprises an epidermal growth factor receptor (EGFR) inhibitor.
13 . The method of claim 12 , wherein the EGFR inhibitor is a receptor tyrosine kinase inhibitor.